A carregar...

Galectin-3: an immune checkpoint target for musculoskeletal tumor patients

In the past decade, the development of immune checkpoint inhibitors in oncological clinical settings was in the forefront. However, the interest in musculoskeletal tumor patients as candidates for checkpoint inhibition remains underserved. Here, we are forwarding evidence proposing that galectin-3 (...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Metastasis Rev
Main Authors: Nakajima, Kosei, Balan, Vitaly, Raz, Avraham
Formato: Artigo
Idioma:Inglês
Publicado em: Springer US 2020
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7897198/
https://ncbi.nlm.nih.gov/pubmed/32929561
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10555-020-09932-4
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!